[1]
Wyse, PhD, J.J., Morasco, PhD, B.J., Dobscha, MD, S.K., Demidenko, BS, M.I., Meath, MPH, T.H.A. and Lovejoy, PhD, MPH, T.I. 2018. Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified. Journal of Opioid Management. 14, 4 (Jul. 2018), 295–303. DOI:https://doi.org/10.5055/jom.2018.0461.